Our Pipeline

Rich and diverse

Our numbers speak volumes. With more than 130 biologics in R&D and 50 products in clinical development, we have one of the strongest, most robust pipelines in the industry.


Cardiovascular, Renal and Metabolism

Phase 1

Phase 1

  • MEDI7219 type-2 diabetes

Phase 2

Phase 2

  • MEDI0382 type-2 diabetes/obesity
  • MEDI5884 cardiovascular disease
  • MEDI6012 cardiovascular disease

Phase 3

Phase 3

LCM Projects

LCM Projects

Oncology

Phase 1

Phase 1

  • Imfinzi + Iressa non-small cell lung cancer
  • Imfinzi + MEDI0562 solid tumours
  • Imfinzi + MEDI9197 solid tumours
  • Imfinzi + RT (platform) CLOVER locally-advanced head and neck squamous cell carcinoma, non-small cell lung cancer, small-cell lung cancer
  • Imfinzi + adavosertib solid tumours
  • Imfinzi + azacitidine myelodysplastic syndrome
  • Imfinzi + dabrafenib + trametinib melanoma
  • Imfinzi + monalizumab solid tumours
  • Imfinzi + oleclumab solid tumours
  • Imfinzi + selumetinib solid tumours
  • Imfinzi + tremelimumab solid tumours
  • Imfinzi + tremelimumab + chemotherapy 1st-line pancreatic ductal adenocarcinoma, oesophageal and small cell lung cancer
  • Imfinzi or Imfinzi + (tremelimumab or danvatirsen) diffuse large B-cell lymphoma
  • MEDI0562 solid tumours
  • MEDI1873 solid tumours
  • MEDI2228 multiple myeloma
  • MEDI3726 prostate cancer
  • MEDI5083 solid tumours
  • MEDI5752 solid tumours
  • MEDI7247 haematological malignancies
  • MEDI9197 solid tumours
  • oleclumab solid tumours
  • oleclumab + AZD4635 EGFRm NSCLC
  • oleclumab + Tagrisso EGFRm NSCLC
  • tremelimumab + MEDI0562 solid tumours

Phase 2

Phase 2

  • Imfinzi solid tumours
  • Imfinzi + AZD5069 or Imfinzi + danvatirsen head and neck squamous cell carcinoma, bladder and NSCLC
  • Imfinzi + Lynparza BAYOU 1st-line unresectable stage IV bladder cancer
  • Imfinzi + MEDI0457 head and neck squamous cell carcinoma
  • Imfinzi + MEDI0680 solid tumours
  • Imfinzi + tremelimumab biliary tract, oesophageal
  • Imfinzi + tremelimumab gastric cancer

Phase 3

Phase 3

  • Imfinzi POTOMAC non muscle invasive bladder cancer
  • Imfinzi + tremelimumab DANUBE 1st-line bladder cancer
  • Imfinzi + tremelimumab EAGLE 2nd-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab HIMALAYA 1st-line hepatocellular carcinoma
  • Imfinzi + tremelimumab KESTREL 1st-line head and neck squamous cell carcinoma
  • Imfinzi + tremelimumab MYSTIC 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab NEPTUNE 1st-line non-small cell lung cancer
  • Imfinzi + tremelimumab + CRT ADRIATIC LD-SCLC
  • Imfinzi + tremelimumab + SoC CASPIAN 1st-line small cell lung cancer
  • Imfinzi + tremelimumab + SoC NILE 1st-line urothelial cancer
  • Imfinzi + tremelimumab + chemo POSEIDON 1st-line non-small cell lung cancer
  • Lumoxiti (moxetumomab ) pasudotox PLAIT 3rd-line hairy cell leukaemia

LCM Projects

LCM Projects

  • Imfinzi PACIFIC locally advanced (stage III) NSCLC
  • Imfinzi PEARL (China) 1st-line non-small cell lung cancer
  • Imfinzi + CRT PACIFIC-2 locally-advanced (stage III) NSCLC

Respiratory

Phase 1

Phase 1

  • MEDI3506 chronic obstructive pulmonary disease

Phase 2

Phase 2

  • tezepelumab atopic dermatitis

Phase 3

Phase 3

  • Fasenra CALIMA SIROCCO ZONDA BISE BORA GREGALE severe uncontrolled asthma
  • tezepelumab NAVIGATOR SOURCE severe, uncontrolled asthma

LCM Projects

LCM Projects

  • Fasenra OSTRO nasal polyposis
  • Fasenra TERRANOVA GALATHEA chronic obstructive pulmonary disease

Other

Phase 1

Phase 1

  • MEDI0700 systemic lupus erythematosus
  • MEDI1341 parkinson's disease
  • MEDI1814 Alzheimer’s disease
  • MEDI7352 osteoarthritis pain

Phase 2

Phase 2

  • MEDI3902 prevention of nosocomial Pseudomonas aeruginosa pneumonia
  • MEDI8852 influenza A treatment
  • MEDI8897 passive RSV prophylaxis
  • anifrolumab lupus nephritis
  • anifrolumab systemic lupus erythematosus (subcutaneous)
  • prezalumab primary Sjögren’s syndrome
  • suvratoxumab prevention of nosocomial Staphylococcus aureus pneumonia

Phase 3

Phase 3

  • anifrolumab TULIP systemic lupus erythematosus

LCM Projects

LCM Projects



AstraZeneca Pipeline

Together with AstraZeneca, we have an exciting and balanced pipeline underpinned by great science. Uniquely positioned with both large and small molecules, the development pipeline forms a robust portfolio of investigational therapies in varied stages of clinical development.